A randomized double-blind comparative study of sublingual immunotherapy for cedar pollinosis

Kimihiro Okubo, Minuro Gotoh, Shigeharu Fujieda, Mitsuhiro Okano, Hirokazu Yoshida, Hiroshi Morikawa, Keisuke Masuyama, Yoshitaka Okamoto, Makoto Kobayashi

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Background: Seasonal allergic rhinitis (SAR) induced by Japanese cedar pollen is a substantial problem in Japan. Sublingual immuno-therapy (SLIT) is safer than conventional antigen-specific immunotherapy, the only treatment modality by which complete cure of the disease can be expected. We investigated the safety and efficacy of SLIT in the treatment of cedar pollinosis patients compared to placebo. Methods: A randomized, placebo-controlled, double-blind study was conducted in 61 cedar pollinosis patients. Increasing doses of standardized Japanese cedar extract or placebo were administered sublingually in intervals ranging from daily to once a week after six weeks. The primary efficacy variable was the mean of the daily total symptom scores (TSS) during the pollen dispersing period. Secondary efficacy variables included the QOL scores and related variables. Results: Primary efficacy variable scores were significantly lower for some days in the SLIT group than in the placebo group (P <.01 or P <.05). Secondary efficacy for the QOL score in SLIT group was almost of half of placebo group. There was no significant difference in the overall incidence of side effects between the SLIT group and the placebo group. Conclusions: SLIT was effective and safe in the treatment of cedar pollinosis.

Original languageEnglish
Pages (from-to)265-275
Number of pages11
JournalAllergology International
Volume57
Issue number3
DOIs
Publication statusPublished - 2008

Fingerprint

Sublingual Immunotherapy
Seasonal Allergic Rhinitis
Double-Blind Method
Placebos
Group Psychotherapy
Cryptomeria
Pollen
Therapeutics
Immunotherapy
Japan
Safety
Antigens
Incidence

Keywords

  • Japanese cedar
  • Placebo-controlled study
  • QOL
  • Seasonal allergic rhinitis

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Okubo, K., Gotoh, M., Fujieda, S., Okano, M., Yoshida, H., Morikawa, H., ... Kobayashi, M. (2008). A randomized double-blind comparative study of sublingual immunotherapy for cedar pollinosis. Allergology International, 57(3), 265-275. https://doi.org/10.2332/allergolint.O-07-514

A randomized double-blind comparative study of sublingual immunotherapy for cedar pollinosis. / Okubo, Kimihiro; Gotoh, Minuro; Fujieda, Shigeharu; Okano, Mitsuhiro; Yoshida, Hirokazu; Morikawa, Hiroshi; Masuyama, Keisuke; Okamoto, Yoshitaka; Kobayashi, Makoto.

In: Allergology International, Vol. 57, No. 3, 2008, p. 265-275.

Research output: Contribution to journalArticle

Okubo, K, Gotoh, M, Fujieda, S, Okano, M, Yoshida, H, Morikawa, H, Masuyama, K, Okamoto, Y & Kobayashi, M 2008, 'A randomized double-blind comparative study of sublingual immunotherapy for cedar pollinosis', Allergology International, vol. 57, no. 3, pp. 265-275. https://doi.org/10.2332/allergolint.O-07-514
Okubo, Kimihiro ; Gotoh, Minuro ; Fujieda, Shigeharu ; Okano, Mitsuhiro ; Yoshida, Hirokazu ; Morikawa, Hiroshi ; Masuyama, Keisuke ; Okamoto, Yoshitaka ; Kobayashi, Makoto. / A randomized double-blind comparative study of sublingual immunotherapy for cedar pollinosis. In: Allergology International. 2008 ; Vol. 57, No. 3. pp. 265-275.
@article{0b5a3c98140f4a90b3dbd90ec98e1598,
title = "A randomized double-blind comparative study of sublingual immunotherapy for cedar pollinosis",
abstract = "Background: Seasonal allergic rhinitis (SAR) induced by Japanese cedar pollen is a substantial problem in Japan. Sublingual immuno-therapy (SLIT) is safer than conventional antigen-specific immunotherapy, the only treatment modality by which complete cure of the disease can be expected. We investigated the safety and efficacy of SLIT in the treatment of cedar pollinosis patients compared to placebo. Methods: A randomized, placebo-controlled, double-blind study was conducted in 61 cedar pollinosis patients. Increasing doses of standardized Japanese cedar extract or placebo were administered sublingually in intervals ranging from daily to once a week after six weeks. The primary efficacy variable was the mean of the daily total symptom scores (TSS) during the pollen dispersing period. Secondary efficacy variables included the QOL scores and related variables. Results: Primary efficacy variable scores were significantly lower for some days in the SLIT group than in the placebo group (P <.01 or P <.05). Secondary efficacy for the QOL score in SLIT group was almost of half of placebo group. There was no significant difference in the overall incidence of side effects between the SLIT group and the placebo group. Conclusions: SLIT was effective and safe in the treatment of cedar pollinosis.",
keywords = "Japanese cedar, Placebo-controlled study, QOL, Seasonal allergic rhinitis",
author = "Kimihiro Okubo and Minuro Gotoh and Shigeharu Fujieda and Mitsuhiro Okano and Hirokazu Yoshida and Hiroshi Morikawa and Keisuke Masuyama and Yoshitaka Okamoto and Makoto Kobayashi",
year = "2008",
doi = "10.2332/allergolint.O-07-514",
language = "English",
volume = "57",
pages = "265--275",
journal = "Allergology International",
issn = "1323-8930",
publisher = "Japanese Society of Allergology",
number = "3",

}

TY - JOUR

T1 - A randomized double-blind comparative study of sublingual immunotherapy for cedar pollinosis

AU - Okubo, Kimihiro

AU - Gotoh, Minuro

AU - Fujieda, Shigeharu

AU - Okano, Mitsuhiro

AU - Yoshida, Hirokazu

AU - Morikawa, Hiroshi

AU - Masuyama, Keisuke

AU - Okamoto, Yoshitaka

AU - Kobayashi, Makoto

PY - 2008

Y1 - 2008

N2 - Background: Seasonal allergic rhinitis (SAR) induced by Japanese cedar pollen is a substantial problem in Japan. Sublingual immuno-therapy (SLIT) is safer than conventional antigen-specific immunotherapy, the only treatment modality by which complete cure of the disease can be expected. We investigated the safety and efficacy of SLIT in the treatment of cedar pollinosis patients compared to placebo. Methods: A randomized, placebo-controlled, double-blind study was conducted in 61 cedar pollinosis patients. Increasing doses of standardized Japanese cedar extract or placebo were administered sublingually in intervals ranging from daily to once a week after six weeks. The primary efficacy variable was the mean of the daily total symptom scores (TSS) during the pollen dispersing period. Secondary efficacy variables included the QOL scores and related variables. Results: Primary efficacy variable scores were significantly lower for some days in the SLIT group than in the placebo group (P <.01 or P <.05). Secondary efficacy for the QOL score in SLIT group was almost of half of placebo group. There was no significant difference in the overall incidence of side effects between the SLIT group and the placebo group. Conclusions: SLIT was effective and safe in the treatment of cedar pollinosis.

AB - Background: Seasonal allergic rhinitis (SAR) induced by Japanese cedar pollen is a substantial problem in Japan. Sublingual immuno-therapy (SLIT) is safer than conventional antigen-specific immunotherapy, the only treatment modality by which complete cure of the disease can be expected. We investigated the safety and efficacy of SLIT in the treatment of cedar pollinosis patients compared to placebo. Methods: A randomized, placebo-controlled, double-blind study was conducted in 61 cedar pollinosis patients. Increasing doses of standardized Japanese cedar extract or placebo were administered sublingually in intervals ranging from daily to once a week after six weeks. The primary efficacy variable was the mean of the daily total symptom scores (TSS) during the pollen dispersing period. Secondary efficacy variables included the QOL scores and related variables. Results: Primary efficacy variable scores were significantly lower for some days in the SLIT group than in the placebo group (P <.01 or P <.05). Secondary efficacy for the QOL score in SLIT group was almost of half of placebo group. There was no significant difference in the overall incidence of side effects between the SLIT group and the placebo group. Conclusions: SLIT was effective and safe in the treatment of cedar pollinosis.

KW - Japanese cedar

KW - Placebo-controlled study

KW - QOL

KW - Seasonal allergic rhinitis

UR - http://www.scopus.com/inward/record.url?scp=53749105914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53749105914&partnerID=8YFLogxK

U2 - 10.2332/allergolint.O-07-514

DO - 10.2332/allergolint.O-07-514

M3 - Article

VL - 57

SP - 265

EP - 275

JO - Allergology International

JF - Allergology International

SN - 1323-8930

IS - 3

ER -